{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicjh4l27hr3kiui364pc4a4bwr7aqcfhahujmxkpfuhei5ohyeu7y",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mgelzvorqcu2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicj7jpotlyflccxeomivxixo6vaqwiudwkq26p3qyc4of22aq7gzq"
    },
    "mimeType": "image/jpeg",
    "size": 82044
  },
  "path": "/2026/03/05/better-ibd-treatments-fda-flexibility-questions-readout-loud/?utm_campaign=rss",
  "publishedAt": "2026-03-05T17:49:06.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "The Readout LOUD",
    "biotechnology",
    "Policy"
  ],
  "textContent": "Spyre Therapeutics CEO Cameron Turtle talks about the search for an IBD treatment on this week's \"The Readout LOUD.\"",
  "title": "Breaching the IBD efficacy ceiling, and sham surgeries",
  "updatedAt": "2026-03-05T18:19:29.000Z"
}